Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China – Biogen

1. Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China  Biogen
2. BIIB: Biogen’s LEQEMBI Application Accepted in China  GuruFocus
3. Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China  marketscreener.com
4. Biogen, Eisai say Leqembi BLA accepted in China  TipRanks
5. Eisai and Biogen Announce Acceptance of Biologics License Application for Subcutaneous LEQEMBI® in China  Quiver Quantitative

Continue Reading